Posted by Michael Wonder on 14 Feb 2022
Axcella Therapeutics announces FDA fast track designation for AXA1125 in NASH
14 February 2022 - EMMPACT Phase 2b clinical trial enrolling well, with interim data expected in mid 2022.
Axcella Therapeutics today announced that the U.S. FDA has granted a fast track designation to AXA1125 for the treatment of non-alcoholic steatohepatitis with liver fibrosis.
